Search In this Thesis
   Search In this Thesis  
العنوان
Role of Annexin A1 in Early Diagnosis of lung Cancer /
المؤلف
Shalouf, Yomna Mohammed.
هيئة الاعداد
باحث / يمنى محمد شلوف
مشرف / إبراهيم إبراهيم المحلاوي
مناقش / رنا حلمي الهلباوي
مناقش / نسرين جمال الدين الهلباوى
الموضوع
Chest Diseases. lung Cancer.
تاريخ النشر
2023.
عدد الصفحات
123 p. :
اللغة
الإنجليزية
الدرجة
ماجستير
التخصص
الطب الرئوي والالتهاب الرئوى
تاريخ الإجازة
11/8/2023
مكان الإجازة
جامعة المنوفية - كلية الطب - قسم أمراض الصدر
الفهرس
Only 14 pages are availabe for public view

from 131

from 131

Abstract

Annexin A1, is a protein that is encoded by the ANXA1 gene in humans. Annexin A1 belongs to the Annexin family of Ca2+ dependent phospholipidbinding proteins that have a molecular weight of approximately 35,000 to 40,000 and are preferentially located on the cytosolic face of the plasma membrane. Annexin A1 protein has an apparent relative molecular mass of 40 kDa with phospholipase A2 inhibitory activity.
Recently it was reported that expression of the immunomodulatory protein Annexin A1 (ANXA1) is enhanced in tumor-associated endothelium, and an antibody targeting a membrane-associated, proteolytically cleaved form of AnxA1 was reported to induce rapid tumor uptake in rodent models, including models of lung cancer .Bronchoscopy is considered the main and most effective method for diagnosing patients with a suspicion of a malignancy in the lung. The diagnosis often depends on a tumor tissue biopsy or broncho-alveolar lavage.
The aim of this study is to assess the role of Annexin A1 in bronchoalveolar lavage and serum in the early diagnosis of lung cancer.
 Inclusion criteria:
1. Both genders were included. 2. Age > 18 years. 3. All patients with lung cancer or lesions suspicious to lung cancer. 4. Patients fit for fiberoptic bronchoscopy (FOB) 5. Patients with non malignant lung diseases.  Exclusion criteria:
6. Patients who refused to be included in this study.
7. Uncooperative or unfit patients to FOB.
8. Patients with severe pulmonary hypertension or uncorrectable coagulopathy.
9. Patients with insufficient biopsies.
10. Other co-existing malignancies as hepatic and pancreatic cancers.
11. Presence of pulmonary metastases.
12. Patients who received chemotherapy and/or radiotherapy.
13. Recent myocardial infarction.
All patients were subjected to detailed history, clinical evaluation , CT chest and routine laboratory investigations( CBC ,PT ,PTT ,Coagulation Profile ,KFT ,LFT , ESR ,CRP and Fasting blood glucose.